8HO

2-[(1-methyl-4-oxidanyl-7-phenoxy-isoquinolin-3-yl)carbonylamino]ethanoic acid

Find entries where: 8HO

is present as a standalone ligand in 5 entries

Find related ligands:

Chemical Component Summary
Name	2-[(1-methyl-4-oxidanyl-7-phenoxy-isoquinolin-3-yl)carbonylamino]ethanoic acid
Identifiers	2-[(1-methyl-4-oxidanyl-7-phenoxy-isoquinolin-3-yl)carbonylamino]ethanoic acid
Formula	C₁₉ H₁₆ N₂ O₅
Molecular Weight	352.341
Type	NON-POLYMER
Isomeric SMILES	Cc1c2cc(ccc2c(c(n1)C(=O)NCC(=O)O)O)Oc3ccccc3
InChI	InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
InChIKey	YOZBGTLTNGAVFU-UHFFFAOYSA-N

Chemical Details
Formal Charge	0
Atom Count	42
Chiral Atom Count	0
Bond Count	44
Aromatic Bond Count	17

Drug Info: DrugBank

DrugBank ID	DB04847
Name	Roxadustat
Groups	approved investigational
Description	Roxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels.[A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323]
Synonyms	Roxadustatum Roxadustat
Brand Names	Evrenzo
Indication	Roxadustat is indicated for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).[L40318]
Categories	Amino Acids Amino Acids, Peptides, and Proteins Antianemic Preparations BCRP/ABCG2 Inhibitors Blood and Blood Forming Organs Cytochrome P-450 CYP2C8 Substrates Cytochrome P-450 Substrates Heterocyclic Compounds, Fused-Ring Hypoxia-Inducible Factor-Proline Dioxygenases, antagonists & inhibitors OAT1/SLC22A6 Substrates OAT3/SLC22A8 Substrates OATP1B1/SLCO1B1 Inhibitors UGT1A9 Substrates
ATC-Code	B03XA05
CAS number	808118-40-3

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Egl nine homolog 1	MANDSGGPGGPSPSERDRQYCELCGKMENLLRCSRCRSSFYCCKEHQRQD...	unknown	inhibitor
Egl nine homolog 2	MDSPCQPQPLSQALPQLPGSSSEPLEPEPGRARMGVESYLPCPLLPSYHC...	unknown	inhibitor
Egl nine homolog 3	MPLGHIMRLDLEKIALEYIVPCLHEVGFCYLDNFLGEVVGDCVLERVKQL...	unknown	inhibitor
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	substrate
UDP-glucuronosyltransferase 1-9	MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLIL...	unknown	substrate
Serum albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	binder
ATP-binding cassette sub-family G member 2	MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS...	unknown	inhibitor
Solute carrier organic anion transporter family member 1B1	MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKS...	unknown	inhibitor
Solute carrier family 22 member 6	MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR...	unknown	substrate
Solute carrier family 22 member 8	MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682